Yang Cheng-Cheng, Yang Xiu-Xia, Zhao Xiao-Jing, Wang Heng, Guo Zi-Han, Jin Kai, Liu Yang, Li Bin-Hui
Department of Ophthalmology, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, Guangdong Province, China.
Department of Ophthalmology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China.
Int J Ophthalmol. 2024 Mar 18;17(3):444-453. doi: 10.18240/ijo.2024.03.05. eCollection 2024.
To evaluate the role of semaphorin 7A (Sema7A) and its associated regulatory mechanisms in modulating the barrier function of cultured human corneal epithelial cells (HCEs).
Barrier models of HCEs were treated with recombinant human Sema7A at concentrations of 0, 125, 250, or 500 ng/mL for 24, 48, or 72h . Transepithelial electrical resistance (TEER) as well as Dextran-fluorescein isothiocyanate (FITC) permeability assays were conducted to assess barrier function. To quantify tight junctions (TJs) such as occludin and zonula occludens-1 (ZO-1) at the mRNA level, reverse transcription-polymerase chain reaction (RT-PCR) analysis was performed. Immunoblotting was used to examine the activity of the nuclear factor-kappa B (NF-κB) signaling pathway and the production of TJs proteins. Immunofluorescence analyses were employed to localize the TJs. Enzyme-linked immunosorbent assay (ELISA) and RT-PCR were utilized to observe changes in interleukin (IL)-1β levels. To investigate the role of NF-κB signaling activation and IL-1β in Sema7A's anti-barrier mechanism, we employed 0.1 µmol/L IκB kinase 2 (IKK) inhibitor IV or 500 ng/mL IL-1 receptor (IL-1R) antagonist.
Treatment with Sema7A resulted in decreased TEER and increased permeability of Dextran-FITC in HCEs through down-regulating mRNA and protein levels of TJs in a time- and dose-dependent manner, as well as altering the localization of TJs. Furthermore, Sema7A stimulated the activation of inhibitor of kappa B alpha (IκBα) and expression of IL-1β. The anti-barrier function of Sema7A was significantly suppressed by treatment with IKK inhibitor IV or IL-1R antagonists.
Sema7A disrupts barrier function through its influence on NF-κB-mediated expression of TJ proteins, as well as the expression of IL-1β. These findings suggest that Sema7A could be a potential therapeutic target for the diseases in corneal epithelium.
评估信号素7A(Sema7A)及其相关调控机制在调节培养的人角膜上皮细胞(HCEs)屏障功能中的作用。
用浓度为0、125、250或500 ng/mL的重组人Sema7A处理HCEs屏障模型24、48或72小时。进行跨上皮电阻(TEER)以及异硫氰酸荧光素(FITC)标记的右旋糖酐通透性测定以评估屏障功能。为了在mRNA水平定量紧密连接(TJ)蛋白如闭合蛋白和紧密连接蛋白1(ZO-1),进行逆转录-聚合酶链反应(RT-PCR)分析。免疫印迹法用于检测核因子-κB(NF-κB)信号通路的活性和TJ蛋白的产生。免疫荧光分析用于定位TJ。采用酶联免疫吸附测定(ELISA)和RT-PCR观察白细胞介素(IL)-1β水平的变化。为了研究NF-κB信号激活和IL-1β在Sema7A抗屏障机制中的作用,我们使用了0.1 μmol/L的IκB激酶2(IKK)抑制剂IV或500 ng/mL的IL-1受体(IL-1R)拮抗剂。
Sema7A处理导致HCEs的TEER降低,FITC标记的右旋糖酐通透性增加,通过以时间和剂量依赖性方式下调TJ的mRNA和蛋白水平,以及改变TJ的定位。此外,Sema7A刺激κBα抑制蛋白(IκBα)的激活和IL-1β的表达。用IKK抑制剂IV或IL-1R拮抗剂处理可显著抑制Sema7A的抗屏障功能。
Sema7A通过影响NF-κB介导的TJ蛋白表达以及IL-1β的表达来破坏屏障功能。这些发现表明Sema7A可能是角膜上皮疾病的潜在治疗靶点。